Becton, Dickinson & Co. Faces Valuation Shift Amid Declining Stock Returns and High Debt

Becton, Dickinson & Co., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation, reflecting a shift in its valuation grade. The company’s valuation has been categorized as expensive, moving from a previous classification. Key financial metrics indicate a P/E ratio that remains unreported due to the company being loss-making, while the Price to Book Value stands at 2.31. The EV to EBIT ratio is noted at 23.78, and the EV to EBITDA is recorded at 13.85. Additionally, the EV to Capital Employed ratio is 1.76, and the EV to Sales ratio is 3.51. The dividend yield is currently at 2.56%, with a Return on Capital Employed (ROCE) of 7.40% and a Return on Equity (ROE) of -3.95%. Despite a flat financial performance in the quarter ending December 2025, the company has experienced a decline in stock returns of -9.32% over the past year, while profits have increased by 13.3%. The company’s debt-equity ratio is notably high at 72.72%, and the cash and equivalents have reached a low of USD 1,582 million. For more insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.